BackNovo Nordisk’s new insulin to hit the market by October
Tresiba, the new basal insulin, is used for the treatment of type 1 and type 2 diabetes
Premium(The company, which has a 61% share of the Indian insulin market, says the rupee’s depreciation is one of the reasons that have affected the commercial launch of this imported medicine in India. )
Mumbai: Tresiba, the new basal insulin by Novo Nordisk A/S, the world’s largest insulin maker, will hit the market by October. Tresiba, which is the brand name for the molecule Degludec, is used for the treatment of type 1 and type 2 diabetes.
Basal insulin helps control blood sugar between meals and during sleep.
“We have always ensured we have a wide range of products to address the growing requirements of patients across genres. Tresiba is one such product that reiterates our commitment and passion for delivering better value to people with diabetes." said Melvin Oscar D’souza, managing director, Novo Nordisk India during the launch.
The company, which has a 61% share of the Indian insulin market, says the rupee’s depreciation is one of the reasons that have affected the commercial launch of this imported medicine in India.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
